Vesper Bio Initiates Phase Ib/Iia Proof Of Concept Study Of VES001 In Asymptomatic Patients With Gene Mutations That Cause Frontotemporal Dementia (FTD)

(MENAFN - PR Newswire) Dosing of VES001 has commenced in patients with causal gene mutations for FTD(GRN), a type of frontotemporal dementia which is invariably fatal This ...

By: menafn